



Brain Cáncer

Malignant Glioma

THE PROBLEM


- ✗ **Life Expectancy.**
Without treatment: 6 months.
With treatment: 2 years.
- ✗ **Quality of Life.**
Neurological and cognitive impairments.
- ✗ **Economic Cost**
Extremely high!

A fast and timely therapy is needed to improve the patient's immune conditions.

OUR SOLUTION


Therapeutic Vaccine Against Brain Cancer

- ✓ Increase patient survival and quality of life
- ✓ Reduce tumor volume
- ✓ Improve the chances of successful surgery




BUSINESS MODEL

MARKET



DEVELOPMENT STAGE



TRL Level 3

Proven efficacy in animal models.

PI

Patent application pending
WO2020/026001 A1.



INVESTMENT

Stage 1 Fundraising

USD 1.3 millions

Financing the cash deficit to ensure the growth plan over the next 18 months

Use - Preclinical testing	USD 900,000 (66%)
Use - CAPEX	USD 120,000 (9%)
Use - Intellectual Property	USD 75,000 (6%)
Use - other operating expenses	USD 250,000 (19%)

In the next 18 months

- 1 Completing preclinical studies in rodents
- 2 Complete preclinical studies in non-rodents
- 3 Obtain patents in MX, US, CA, EU and CN

Contact:
Francisco Lozano Martínez
flozano@newgenesis.cl

Raúl Vázquez Cassani
rvazquez@newgenesis.cl